Revenue ($USD): $2,909,800,000
R&D spend: $484,200,000.00
Employees: 7,600
Fiscal year end: 12/31/22
CEO: Kevin Sayer
Soon after, a new Medicare guidelineimplemented in Aprilincreased the addressable market for the company’s CGM.
The San Diego-based company is nowshifting its focus toward using its technology beyond diabetes management, with eyes on bringing its sensors to even more users.–SW